These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36856592)

  • 1. Fibrinogen-Aα THR312ALA Polymorphism is Associated to Chronic Thromboembolic Pulmonary Hypertension in Turkey.
    Çörtük M; Yıldızeli B; Kurar E; Kayış SA; Tanrıverdi E; Çetinkaya E
    Anatol J Cardiol; 2023 Mar; 27(3):153-159. PubMed ID: 36856592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinogen Aα Thr312Ala polymorphism specifically contributes to chronic thromboembolic pulmonary hypertension by increasing fibrin resistance.
    Li JF; Lin Y; Yang YH; Gan HL; Liang Y; Liu J; Yang SQ; Zhang WJ; Cui N; Zhao L; Zhai ZG; Wang J; Wang C
    PLoS One; 2013; 8(7):e69635. PubMed ID: 23894515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinogen Aalpha Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension.
    Suntharalingam J; Goldsmith K; van Marion V; Long L; Treacy CM; Dudbridge F; Toshner MR; Pepke-Zaba J; Eikenboom JC; Morrell NW
    Eur Respir J; 2008 Apr; 31(4):736-41. PubMed ID: 18057060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population.
    Dilge Taşkın B; Kula S; Ergün MA; Altun D; Olguntürk R; Tunaoğlu FS; Oğuz AD; Gürsel T
    Anatol J Cardiol; 2016 Oct; 16(10):791-796. PubMed ID: 27182616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence of VKORC1*3 (G9041A) genetic polymorphism in north Indians: A study on patients with cardiac disorders on acenocoumarol.
    Sehgal T; Hira JK; Ahluwalia J; Das R; Vijayvergiya R; Rana SS; Varma N
    Drug Discov Ther; 2015 Dec; 9(6):404-10. PubMed ID: 26781925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The frequency of CYP2C9, VKORC1, and CYP4F2 polymorphisms in Russian patients with high thrombotic risk.
    Ivashchenko D; Rusin I; Sychev D; Grachev A
    Medicina (Kaunas); 2013; 49(12):517-21. PubMed ID: 24858991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between polymorphisms of VKORC1 and CYP2C9 genes with warfarin maintenance dose in a group of warfarin users in Birjand city, Iran.
    Fereidouni M; Moossavi M; Kazemi T; Nouranihassankiade S; Asghari A
    J Cell Biochem; 2019 Jun; 120(6):9588-9593. PubMed ID: 30525241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.
    Sridharan K; Al Banna R; Malalla Z; Husain A; Sater M; Jassim G; Otoom S
    Pharmacol Rep; 2021 Oct; 73(5):1405-1417. PubMed ID: 33811620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
    Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
    Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
    Ghozlan MF; Foad DA; Darwish YW; Saad AA
    Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
    Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
    Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639GKaur A; Khan F; Agrawal SS; Kapoor A; Agarwal SK; Phadke SR
    Indian J Med Res; 2013 Jan; 137(1):203-9. PubMed ID: 23481074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of VKORC1 and CYP2C9 Polymorphisms on Daily Acenocoumarol Dose Requirement in South Indian Patients With Mechanical Heart Valves.
    Kalpana SR; Bharath G; Manjunath CN; Christopher R
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):876-882. PubMed ID: 27335128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of
    Akdeniz CS; Cevik M; Canbolat IP; Yurdakul S; Cagatay P; Ciftci C; Karaalp A; Susleyici B
    Future Cardiol; 2020 Nov; 16(6):645-654. PubMed ID: 32583677
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of vitamin K epoxide reductase complex 1 gene polymorphisms on warfarin control in Japanese patients with left ventricular assist devices (LVAD).
    Nakagita K; Wada K; Mukai Y; Uno T; Nishino R; Matsuda S; Takenaka H; Terakawa N; Oita A; Takada M
    Eur J Clin Pharmacol; 2018 Jul; 74(7):885-894. PubMed ID: 29781049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.
    Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary OA
    Ir J Med Sci; 2014 Jun; 183(2):161-72. PubMed ID: 23800980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The VKORC1 and CYP2C9 genotypes significantly effect Vitamin K antagonist dosing only in patients over the age of 20years.
    Nowak-Göttl U; Dietrich K; Kruempel A; Geisen C; Mitchell LG
    Blood Cells Mol Dis; 2017 Sep; 67():54-58. PubMed ID: 28284562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Genetic Polymorphisms of CYP2C9 and VKORC1 with Bleeding Following Warfarin: A Case-Control Study.
    Sridharan K; Modi T; Bendkhale S; Kulkarni D; Gogtay NJ; Thatte UM
    Curr Clin Pharmacol; 2016; 11(1):62-8. PubMed ID: 26777610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
    Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: Results of a 5 years audit.
    Biswas M; Bendkhale SR; Deshpande SP; Thaker SJ; Kulkarni DV; Bhatia SJ; Rajadhyaksha AG; Gogtay NJ; Thatte UM
    Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S13-S19. PubMed ID: 30595245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.